TY - JOUR T1 - Radiotherapy Plus Total Androgen Block <em>Versus</em> Radiotherapy Plus LHRH Analog Monotherapy for Non-metastatic Prostate Cancer JF - Anticancer Research JO - Anticancer Res SP - 3139 LP - 3143 VL - 38 IS - 5 AU - GIULIA MARVASO AU - ANNA VIOLA AU - CRISTIANA FODOR AU - BARBARA A. JERECZEK-FOSSA Y1 - 2018/05/01 UR - http://ar.iiarjournals.org/content/38/5/3139.abstract N2 - Background/Aim: Patients with locally advanced prostate cancer are generally treated with radiotherapy (RT) which can be combined with hormonal therapy. RT plus monotherapy with luteinizing hormone-releasing hormone (LHRH) analog triptorelin was compared to RT plus total androgen block (TAB). Patients and Methods: A retrospective study was carried out on patients with locally advanced prostate cancer comparing RT plus monotherapy versus RT plus TAB. Results: For overall survival, no differences between patients receiving RT with monotherapy and those treated with TAB were observed. A trend favoring use of TAB was found for progression-free survival. No differences in late gastrointestinal and genitourinary toxicities were reported. Conclusion: This study suggests that monotherapy with LHRH is as effective as TAB, which is important in selecting appropriate treatment considering that TAB can have higher risks of adverse events and reduce the quality of life of patients. ER -